GlassScriptPhysician profile
Andreas Gonzalez
NPI 1679968572
$10,752.36
in general payments reported to CMS, 2019-2025
19 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $124 · 2021: $1,175 · 2022: $959 · 2023: $3,434 · 2024: $2,767 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,238 · Consulting Fee: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.44 |
| Consulting Fee | $3,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $3,087.11 | 2020-2024 | |
| Alcon Vision LLC | $2,082.71 | 2019-2025 | Constellation, Ngenuity, Wavelight Refractive Suite |
| Regeneron Pharmaceuticals, INC. | $1,555.82 | 2023-2025 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $1,111.17 | 2020-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $599.40 | 2022-2025 | Vabysmo |
| Mallinckrodt Enterprises LLC | $373.95 | 2019 | |
| Abbvie INC. | $363.32 | 2022-2024 | |
| Glaukos Corporation | $237.40 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $214.49 | 2022-2024 | Eylea, Eylea Hd |
| Astellas Pharma US INC | $194.90 | 2023-2025 | Izervay |
| Genentech, INC. | $181.45 | 2022 | |
| Sun Pharmaceutical Industries INC. | $148.01 | 2024-2025 | |
| New World Medical,INC. | $140.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $114.57 | 2019-2023 | Tecnis Simplicity, Veritas Vision System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $93.04 | 2022-2024 | Syfovre |
| Harrow Eye, LLC | $57.22 | 2025 | Iheezo, Triesence |
| Bausch & Lomb Americas INC. | $48.32 | 2022-2025 | Xipere |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.